Noncoding RNAs orchestrate cell growth, death and drug resistance in renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Renal cell carcinoma (RCC) is a significant health concern.
• Understanding the molecular mechanisms, including the role of noncoding RNAs (ncRNAs), is crucial for improving RCC diagnosis and treatment.
• ncRNAs are increasingly recognized for their involvement in various cancers.

Purpose of the Study:

• To investigate the expression patterns of specific ncRNAs (miR-196a2, miR-499a, H19, MALAT1, GAS5) in renal cell carcinoma.
• To explore the correlation between the expression of these ncRNAs and their target genes.
• To assess the prognostic value of identified ncRNAs in RCC patients.

Main Methods:

• Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was employed to measure the expression levels of selected ncRNAs and target transcripts.
• Expression data was compared between cancerous and paired non-cancerous renal tissues.
• Statistical analysis was performed to associate ncRNA expression with clinical parameters and patient prognosis.

Main Results:

• Significant alterations in the expression of ncRNAs were observed in RCC tissues compared to non-cancerous tissues.
• Up-regulation of miR-196a2 and MALAT1, and down-regulation of miR-499a and GAS5 were prominent findings.
• Down-regulation of GAS5, PDCD4, and DFFA was significantly associated with advanced tumor grade, larger tumor size, and metastasis.

Conclusions:

• Specific ncRNAs, including miR-196a2, miR-499a, MALAT1, and GAS5, exhibit altered expression in renal cell carcinoma.
• The expression levels of certain ncRNAs (GAS5, PDCD4, DFFA) correlate with poor prognostic indicators in RCC.
• These ncRNAs hold potential as theranostic biomarkers for renal cell carcinoma, aiding in diagnosis and treatment strategies.